News Network

New Frontiers in Breast Cancer: Updates and Advances in Treatment

May 11th 2022

Experts Joyce A. O’Shaughnessy, MD, and Sara A. Hurvitz, MD, provide comprehensive updates on the optimal workup and management of patients with breast cancer.

Updates in Metastatic HER2 Positive Breast Cancer Treatment

April 21st 2022

Expert perspectives on novel management of HER2+ metastatic breast cancer in the context of recent clinical trials and FDA approvals.

OncLive News Network On Location: ASCO GU 2022

February 17th 2022

Join us LIVE at this year's 2022 Genitourinary Cancers Symposium! OncLive® will broadcast a series of interviews with top thought leaders across cancers of the bladder, prostate, and kidney. The experts will share their insights and reactions to the pivotal data presented during the conference.

ctDNA in Pancreatic and Colorectal Cancer

February 15th 2022

How ctDNA testing is being investigated and used in pancreatic and colorectal cancer in the era of precision medicine.

Updates in CLL: Strategies for Managing Toxicities and Special Patient Considerations

February 11th 2022

Two experts lead a discussion about chronic lymphocytic leukemia (CLL), focusing on updates in management and special considerations when treating with BTK inhibitors.

Updates in SCLC: Advances in Treatment

January 31st 2022

Drs Carl M. Gay and Jared Weiss highlight novel treatment advances for newly diagnosed and relapsed/refractory small cell lung cancer.

Immune Checkpoint Inhibitors in First-line Treatment of Metastatic NSCLC

January 31st 2022

Hossein Borghaei, DO, MS, and Martin Reck, MD, PhD, highlight recent advances and use of immune checkpoint inhibitors in the treatment of first-line metastatic non-small cell lung cancer.

Updates on the Potential Role of ctDNA in Managing Breast Cancer Patients Across the Disease Continuum

January 27th 2022

Shared insight on the clinical impact circulating tumor DNA testing has had on the management of patients with breast cancer.

Optimizing Imaging in ER-positive Metastatic Breast Cancer to Improve Clinical Outcomes

December 22nd 2021

Gary Ulaner, MD, PhD and Jeremy Force, DO discuss the role of various strategies to detect estrogen receptor (ER)-positive breast cancer, with particular focus on the role of 18F-FES-PET imaging in diagnosis and treatment of ER-positive breast cancer and in improving patient outcomes.

Updates in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma from ASH 2021

December 21st 2021

Experts review key updates in multiple myeloma management from the ASH 2021 annual meeting.

Post-Conference Perspectives: Updates on the Treatment of EGFR Mutant Early-Stage and Advanced NSCLC

December 20th 2021

Experts Share Insights on NCCN Guidelines for Metastatic TNBC

December 17th 2021

As part of its Speaking Out video series, CURE spoke with Rebecca Moroose, MD, from Orlando Health Cancer Institute, and Virginia G. Kaklamani, MD, from UT Health San Antonio, about the National Comprehensive Cancer Network guidelines and what they mean for patients.

OncLive News Network: On Location at ASH 2021

December 11th 2021

Join us LIVE at this year's 2021 ASH Annual Meeting! OncLive® will broadcast a series of interviews with top thought leaders across hematologic malignancies. The experts will share their insights and reactions to the pivotal data presented during the conference.

Post-Conference Perspectives: Understanding HER2-Low Breast Cancer

December 9th 2021

Experts Sandra M. Swain, MD, and Zahi Mitri, MD, MS, reflect on HER2-low breast cancer as a subset of disease and discuss novel therapeutic agents that may improve patient outcomes in this setting.

Updates in CLL: What’s on the Horizon in CLL?

December 8th 2021

Nitin Jain, MD, and Richard R. Furman, MD, review the role of BTK inhibitors and emerging therapies on the horizon for the management of CLL.

Post-Conference Perspectives: Balstilimab In The Treatment of Cervical Cancer

November 30th 2021

Emerging Therapies in Relapsed or Refractory Multiple Myeloma

November 12th 2021

Kenneth Shain, MD, PhD reviews advances in treatment of relapsed and refractory multiple myeloma and data presented at 2021 International Myeloma Workshop.

Updates in CLL: Optimizing Testing Rates

November 4th 2021

Preferences for conducting molecular testing in patients with chronic lymphocytic leukemia to guide treatment decisions based on evolving novel combination regimens used as frontline therapy.

Approval of Tisotumab Vedotin in The Treatment of Cervical Cancer

November 1st 2021

Expert gynecologic oncologist Rebecca Arend, MD, MPH, addresses data from the 2021 ESMO meeting and the approval of tisotumab vedotin for patients with cervical cancer.

Antibody-Drug Conjugates in NSCLC: Update on TROPION-PanTumor01 Data

October 22nd 2021

Rebecca Suk Heist, MD, MPH, and Solange Peters, MD, PhD, discuss data updates from the TROPION-PanTumor01 study that impact the use of antibody-drug conjugates as a therapy option for patients with second-line metastatic non-small cell lung cancer.